News | Halozyme
Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below: Press Releases.
Halozyme Announces FDA Approval of Roche's Tecentriq …
Sep 13, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and...
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And …
Nov 3, 2024 · Taking into account the latest results, the current consensus from Halozyme Therapeutics' ten analysts is for revenues of US$1.15b in 2025. This would reflect a substantial 22% increase on its ...
Halozyme Announces Positive Clinical Data of its High-Volume …
Oct 16, 2023 · Data Highlights. 96% of participants stated that they would be willing to receive the injection again. 90% of participants indicated feeling either no pain or mild pain immediately after injection....
Halozyme Therapeutics, Inc. (HALO) Latest Stock News
Get the latest Halozyme Therapeutics, Inc. (HALO) stock news and headlines to help you in your trading and investing decisions.
Halozyme Announces FDA Approval of Roche's Subcutaneous …
Sep 13, 2024 · The FDA approval is based on pivotal data from the Phase III OCARINA II trial, which showed non-inferior levels of OCREVUS in the blood when administered subcutaneously, and a safety and efficacy...
Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 5, 2024 · Halozyme Q3 Financial Highlights (Halozyme) As a result, Halozyme decided to update their full-year guidance, with their EPS going from $3.65-$4.05 to $4.00-$4.20. Halozyme is also projecting ...
Halozyme Announces FDA Approval of Roche's Subcutaneous
SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS...
Halozyme Announces Takeda Receives FDA Approval for …
SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of chronic inflammatory ...
Foster & Motley Inc. Buys Shares of 10,650 Halozyme
5 days ago · Insider Activity at Halozyme Therapeutics. In related news, Director Matthew L. Posard sold 10,000 shares of the business's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares in the ...